annual FCF:
-$434.18M+$87.39M(+16.76%)Summary
- As of today (July 7, 2025), RARE annual free cash flow is -$434.18 million, with the most recent change of +$87.39 million (+16.76%) on December 31, 2024.
- During the last 3 years, RARE annual FCF has fallen by -$22.39 million (-5.44%).
- RARE annual FCF is now -6712.79% below its all-time high of -$6.37 million, reached on December 31, 2011.
Performance
RARE Free cash flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly FCF:
-$182.80M-$102.64M(-128.05%)Summary
- As of today (July 7, 2025), RARE quarterly free cash flow is -$182.80 million, with the most recent change of -$102.64 million (-128.05%) on March 31, 2025.
- Over the past year, RARE quarterly FCF has increased by +$21.14 million (+10.37%).
- RARE quarterly FCF is now -319.53% below its all-time high of $83.27 million, reached on June 30, 2020.
Performance
RARE quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
-$413.04M+$21.14M(+4.87%)Summary
- As of today (July 7, 2025), RARE TTM free cash flow is -$413.04 million, with the most recent change of +$21.14 million (+4.87%) on March 31, 2025.
- Over the past year, RARE TTM FCF has increased by +$130.57 million (+24.02%).
- RARE TTM FCF is now -6283.93% below its all-time high of -$6.47 million, reached on March 31, 2013.
Performance
RARE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free cash flow Formula
FCF = Cash From Operations − CAPEX
RARE Free cash flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.8% | +10.4% | +24.0% |
| 3 y3 years | -5.4% | -1.7% | +0.7% |
| 5 y5 years | -17.3% | -67.3% | -103.4% |
RARE Free cash flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -5.4% | +17.6% | -166.4% | +10.4% | at high | +25.4% |
| 5 y | 5-year | -146.5% | +17.6% | -319.5% | +10.4% | -135.7% | +25.4% |
| alltime | all time | -6712.8% | +17.6% | -319.5% | +10.4% | -6283.9% | +25.4% |
RARE Free cash flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$182.80M(+128.1%) | -$413.04M(-4.9%) |
| Dec 2024 | -$434.18M(-16.8%) | -$80.16M(+16.8%) | -$434.18M(-1.2%) |
| Sep 2024 | - | -$68.61M(-15.8%) | -$439.53M(-10.8%) |
| Jun 2024 | - | -$81.47M(-60.1%) | -$492.48M(-9.4%) |
| Mar 2024 | - | -$203.94M(+138.5%) | -$543.61M(+4.2%) |
| Dec 2023 | -$521.57M(-1.0%) | -$85.50M(-29.7%) | -$521.57M(-5.7%) |
| Sep 2023 | - | -$121.57M(-8.3%) | -$553.38M(+0.0%) |
| Jun 2023 | - | -$132.60M(-27.1%) | -$553.20M(+4.6%) |
| Mar 2023 | - | -$181.90M(+55.1%) | -$528.78M(+0.4%) |
| Dec 2022 | -$526.59M(+27.9%) | -$117.31M(-3.4%) | -$526.59M(+9.8%) |
| Sep 2022 | - | -$121.39M(+12.2%) | -$479.67M(+9.4%) |
| Jun 2022 | - | -$108.18M(-39.8%) | -$438.49M(+5.5%) |
| Mar 2022 | - | -$179.71M(+155.3%) | -$415.73M(+1.0%) |
| Dec 2021 | -$411.79M(+133.8%) | -$70.39M(-12.2%) | -$411.79M(-3.3%) |
| Sep 2021 | - | -$80.21M(-6.1%) | -$425.79M(+3.5%) |
| Jun 2021 | - | -$85.43M(-51.4%) | -$411.33M(+69.5%) |
| Mar 2021 | - | -$175.76M(+108.3%) | -$242.64M(+37.8%) |
| Dec 2020 | -$176.13M(-52.4%) | -$84.40M(+28.4%) | -$176.13M(+0.5%) |
| Sep 2020 | - | -$65.75M(-179.0%) | -$175.27M(-13.7%) |
| Jun 2020 | - | $83.27M(-176.2%) | -$203.06M(-46.7%) |
| Mar 2020 | - | -$109.25M(+30.8%) | -$380.63M(+2.8%) |
| Dec 2019 | -$370.21M(+25.6%) | -$83.54M(-10.7%) | -$370.21M(+7.7%) |
| Sep 2019 | - | -$93.54M(-0.8%) | -$343.72M(+7.3%) |
| Jun 2019 | - | -$94.30M(-4.6%) | -$320.37M(+5.6%) |
| Mar 2019 | - | -$98.83M(+73.3%) | -$303.52M(+3.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$294.64M(+14.8%) | -$57.05M(-18.7%) | -$294.64M(-8.0%) |
| Sep 2018 | - | -$70.19M(-9.4%) | -$320.32M(+2.3%) |
| Jun 2018 | - | -$77.45M(-13.9%) | -$313.16M(+9.9%) |
| Mar 2018 | - | -$89.95M(+8.7%) | -$284.90M(+11.0%) |
| Dec 2017 | -$256.64M(+49.9%) | -$82.72M(+31.3%) | -$256.64M(+15.5%) |
| Sep 2017 | - | -$63.03M(+28.1%) | -$222.26M(+16.4%) |
| Jun 2017 | - | -$49.20M(-20.2%) | -$190.98M(+2.4%) |
| Mar 2017 | - | -$61.69M(+27.6%) | -$186.48M(+8.9%) |
| Dec 2016 | -$171.16M(+54.3%) | -$48.35M(+52.3%) | -$171.16M(+3.6%) |
| Sep 2016 | - | -$31.75M(-29.0%) | -$165.18M(-0.5%) |
| Jun 2016 | - | -$44.70M(-3.6%) | -$166.02M(+19.3%) |
| Mar 2016 | - | -$46.37M(+9.5%) | -$139.19M(+25.5%) |
| Dec 2015 | -$110.93M(+137.1%) | -$42.37M(+30.0%) | -$110.93M(+36.2%) |
| Sep 2015 | - | -$32.58M(+82.3%) | -$81.47M(+35.0%) |
| Jun 2015 | - | -$17.87M(-1.4%) | -$60.36M(+12.4%) |
| Mar 2015 | - | -$18.12M(+40.4%) | -$53.71M(+14.8%) |
| Dec 2014 | -$46.78M(+48.0%) | -$12.91M(+12.5%) | -$46.78M(+6.9%) |
| Sep 2014 | - | -$11.47M(+2.2%) | -$43.78M(+11.5%) |
| Jun 2014 | - | -$11.22M(+0.2%) | -$39.26M(+8.1%) |
| Mar 2014 | - | -$11.19M(+13.0%) | -$36.33M(+14.9%) |
| Dec 2013 | -$31.61M(+132.5%) | -$9.90M(+42.5%) | -$31.61M(+45.6%) |
| Sep 2013 | - | -$6.95M(-16.1%) | -$21.70M(+47.1%) |
| Jun 2013 | - | -$8.29M(+28.1%) | -$14.76M(+128.1%) |
| Mar 2013 | - | -$6.47M | -$6.47M |
| Dec 2012 | -$13.60M(+113.3%) | - | - |
| Dec 2011 | -$6.37M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual free cash flow?
- What is the all time high annual FCF for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual FCF year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly free cash flow?
- What is the all time high quarterly FCF for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly FCF year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM free cash flow?
- What is the all time high TTM FCF for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM FCF year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual free cash flow?
The current annual FCF of RARE is -$434.18M
What is the all time high annual FCF for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual free cash flow is -$6.37M
What is Ultragenyx Pharmaceutical Inc. annual FCF year-on-year change?
Over the past year, RARE annual free cash flow has changed by +$87.39M (+16.76%)
What is Ultragenyx Pharmaceutical Inc. quarterly free cash flow?
The current quarterly FCF of RARE is -$182.80M
What is the all time high quarterly FCF for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly free cash flow is $83.27M
What is Ultragenyx Pharmaceutical Inc. quarterly FCF year-on-year change?
Over the past year, RARE quarterly free cash flow has changed by +$21.14M (+10.37%)
What is Ultragenyx Pharmaceutical Inc. TTM free cash flow?
The current TTM FCF of RARE is -$413.04M
What is the all time high TTM FCF for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM free cash flow is -$6.47M
What is Ultragenyx Pharmaceutical Inc. TTM FCF year-on-year change?
Over the past year, RARE TTM free cash flow has changed by +$130.57M (+24.02%)